Zachary P. Shultz

Zachary P. Shultz

Auto-generated profile, based on publicly available information

Zachary P. Shultz

Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
LCLihong Chen
Lihong Chen
ZSZachary P. Shultz
Zachary P. Shultz
MSMarianna Sansone
Marianna Sansone
BFBin Fang
Bin Fang
XLXiang Liu
Xiang Liu
JCJiandong Chen
Jiandong Chen
The bromodomain-containing protein, transcription factor IID subunit 1 (TAF1; transcription factor II-250), is the largest component of the multiprotein assembly transcription factor IID, a dynamic complex that serves as a general factor for transcription initiation. CRISPR and RNAi screens of pan-cancer cell lines revealed that TAF1 is broadly required for optimal cell growth and survival, but a subset of cell lines showed enhanced TAF1 dependence. These observations suggest that TAF1 has the potential to serve as a therapeutic target in sensitive tumors. Current approaches employed to target TAF1 are limited to monovalent small-molecule inhibitors of the bromodomain. However, recent studies showed that such inhibitors lack cancer cell kill potential. We applied a structure-guided approach to generate cereblon recruiting Proteolysis Targeting Chimera (PROTAC) degraders of TAF1 using the chemical scaffolds of ceralasertib and GNE371. We present evidence that GNE371-based PROTACs are effective in degradation of TAF1 at concentrations as low as 1 nmol/L. TAF1 depletion activated p53 and induced apoptosis in acute myeloid leukemia (AML) cell lines and certain solid tumor cells. An in vivo active TAF1 PROTAC inhibited the growth of AML tumor xenografts. The results showed that inhibition of the bromodomain is not sufficient to inactivate TAF1 functions, whereas a PROTAC approach induces strong biological effects. Furthermore, TAF1 PROTACs have therapeutic potential against AML and other sensitive tumors.

23 July 2026 in Science
Verified
Journal Article
Closed access
ZSZachary P. Shultz
Zachary P. Shultz
ALAnsar Lee-Sam
Ansar Lee-Sam
YCYun-Pu Chang
Yun-Pu Chang
LSLuxin Sun
Luxin Sun
DGDylan Grassie
Dylan Grassie
JLJustin M. Lopchuk
Justin M. Lopchuk
Covalent inhibition continues to gain momentum as a strategy for selective protein modulation in both therapeutic and chemical biology contexts. Covalent reactive groups (CRGs) typically engage nucleophilic residues such as cysteine, resulting in targeted protein inactivation. However, common electrophiles such as acrylamides often suffer from nonselective reactivity, leading to off-target effects and toxicity. To overcome these limitations, we developed a modular sulfur(IV) reagent platform for the mild, late-stage installation of sulfonyl- and sulfonimidoyl-bicyclobutane motifs with complete cysteine selectivity. This methodology enables access to diverse sulfur(VI) CRGs with tunable strain-release reactivity. Incorporation into US Food and Drug Administration–approved covalent inhibitors demonstrated effective bioisosteric replacement of acrylamides and the potential of strain-release CRGs for selective protein targeting. Preclinical studies in mice have validated this approach, highlighting its promise for next-generation covalent drug design.

3 November 2025
Verified
Other
Open access
LCLihong Chen
Lihong Chen
ZSZachary P. Shultz
Zachary P. Shultz
MSMarianna Sansone
Marianna Sansone
BFBin Fang
Bin Fang
XLXiang Liu
Xiang Liu
JCJiandong Chen
Jiandong Chen
Supplemental Figure 2. TAF1 PROTAC has potent growth inhibition activity against AML cells.

3 November 2025
Verified
Other
Open access
LCLihong Chen
Lihong Chen
ZSZachary P. Shultz
Zachary P. Shultz
MSMarianna Sansone
Marianna Sansone
BFBin Fang
Bin Fang
XLXiang Liu
Xiang Liu
JCJiandong Chen
Jiandong Chen
Supplemental Table 1. Cell line sensitivity to TAF1 PROTAC induced cell death. Cells were treated with 200 nM ZS1-958 or 50 nM ZS3-025 for 48 to 96 hr. Apoptosis was determined by morphology and PARP cleavage.

3 November 2025
Verified
Other
Open access
LCLihong Chen
Lihong Chen
ZSZachary P. Shultz
Zachary P. Shultz
MSMarianna Sansone
Marianna Sansone
BFBin Fang
Bin Fang
XLXiang Liu
Xiang Liu
JCJiandong Chen
Jiandong Chen
Supplemental Figure 1. TAF1 ligands used for PROTAC development.

3 November 2025
Verified
Other
Open access
LCLihong Chen
Lihong Chen
ZSZachary P. Shultz
Zachary P. Shultz
MSMarianna Sansone
Marianna Sansone
BFBin Fang
Bin Fang
XLXiang Liu
Xiang Liu
JCJiandong Chen
Jiandong Chen
Supplemental Table 3. Proteomics analysis of proteins affected by ZS3-046 treatment.